Eledon Pharmaceuticals recently announced major operational milestones, including preparations for its upcoming global Phase 3 trial evaluating tegoprubart for kidney transplant rejection prevention. The enterprise also established a strategic partnership with Natera to incorporate advanced cell-free DNA monitoring tools into its trials, and reported strong clinical updates at major medical congresses detailing sustained efficacy across both renal and islet cell transplantation settings.